Immunovant (IMVT) Non-Current Deffered Revenue (2019)
Immunovant's (IMVT) quarterly Non-Current Deffered Revenue came in at $4.0 million in Q3 2019, little changed on a QoQ basis from $4.0 million in Q2 2019.
Powered by 
Analysis
Immunovant (IMVT) Non-Current Deffered Revenue (2019) Analysis & Trends
Immunovant (IMVT) has 1 years of Non-Current Deffered Revenue data on file, last reported at $4.0 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Immunovant | 8.04 Bn | 8.04 Bn | - | - |